Artiva Biotherapeutics

32 articles about Artiva Biotherapeutics

• Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

  4/17/2024

  Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the first patient has been dosed in its Phase 1 trial of AlloNK®.

• Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis

  2/22/2024

  Artiva Biotherapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AlloNK®.

• Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

  11/8/2023

  Artiva Biotherapeutics, Inc. today announced it has been awarded Immunology Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry.

• Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis

  8/16/2023

  Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK ® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis.

• Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

  5/25/2023

  Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, announced the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.

• Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

  4/26/2023

  Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago.

• Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101

  1/31/2023

  Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AB-101.

• Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

  11/10/2022

  Artiva Biotherapeutics, Inc. announced today the presentation of activity and efficacy preclinical data for AB-101 with several combinations of therapeutic monoclonal antibodies in multiple preclinical models of cancer.

• Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition

  11/3/2022

  Artiva Biotherapeutics, Inc. announced today the presentation of preclinical efficacy data combining anti-CD38 antibodies with AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, in multiple myeloma models.

• Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

  11/3/2022

  Affimed N.V. (Nasdaq: AFMD) (“Affimed”), and Artiva Biotherapeutics Inc. (“Artiva”), both immuno-oncology companies focused on developing and commercializing therapies utilizing the innate immune system, today announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed’s Innate Cell Engager (ICE®) AFM13 and Artiva’s cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101.

• Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

  10/5/2022

  Artiva Biotherapeutics, Inc. announced today that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC).

• 

  FDA Review: ClearPoint Neuro, Oncopeptides, Iterative Scopes and More

  9/23/2022

  The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.

• Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors

  9/20/2022

  Artiva Biotherapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for AB-201.

• Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities

  6/13/2022

  Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic, natural killer cell therapies that are safe and accessible to cancer patients, announced the official opening of the company’s U.S. corporate headquarters and R&D laboratory facilities at the Alexandria Tech Center in San Diego.

• Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer

  6/6/2022

  Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer cell therapies that are safe and accessible to cancer patients, announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer.

• Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board

  5/5/2022

  Artiva Biotherapeutics, Inc. today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors.

• Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers

  4/11/2022

  Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an agreement with Merck, known as MSD outside the United States and Canada.

• Artiva Biotherapeutics Appoints Laura Bessen, M.D., to Its Board of Directors

  3/3/2022

  Artiva Biotherapeutics, Inc., an oncology company with a mission to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, today announced the appointment of Laura Bessen, M.D., as an independent member of the Company’s board of directors.

• Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer

  1/4/2022

  Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Christopher Horan as Chief Technical Operations Officer.

• Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting

  10/21/2021

  Artiva Biotherapeutics, Inc., (“Artiva”) an oncology company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell-based therapies to treat cancer, today announced an upcoming presentation describing AB-201, an anti-HER2 CAR-NK cell therapy candidate, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021.